Arbutus biopharma provides update on the phase 2a combination trial with ab-729 and a capsid inhibitor

Triple combination clinical trial evaluating ab-729, an rnai therapeutic, vebicorvir, assembly biosciences' core inhibitor, and nucleos(t)ide analog continues with data expected in 2h 2022
ABUS Ratings Summary
ABUS Quant Ranking